Diplomat acquires 8th Day Software, names founder CIO
FLINT, Mich. — Diplomat Pharmacy has made its second acquisition in two months, expanding the service capabilities of its EnvoyHealth support division and bringing on a new chief information officer in the process. The company has acquired 8th Day Software and Consulting, naming founder Dave Loschinskey CIO.
With the acquisition, EnvoyHealth can now offer its healthcare partners such services as IT outsourcing, consulting and product development.
"In an interoperable world, technology delivers comprehensive insight and sustainable value for patients and healthcare partners," said Jennifer Cretu, senior vice president of pharma services and marketing at Diplomat.
Loschinskey founded 8th Day in 2013, which has experience building technology for such services as patient engagement, reporting, hub management, payer services and more. In his new position, Loschinskey, who has more than 20 years’ experience in software development and technology, will have oversight for Diplomat’s IT product strategy and day-to-day operations, with a focus on the specialty pharmacy space.
"The health care market has shown significant demand for information technology services," Diplomat CEO and chairman Phil Hagerman said. "Dave built 8th Day along with past Accredo leaders, and their unique healthcare experience will bring new opportunities to provide better and broader services for our customers. Diplomat continues to move its analytics capabilities up the business intelligence curve from descriptive to predictive."
Before founding 8th Day, Loschinskey was with Accredo — which joined Medco and is now Express Scripts’ specialty pharmacy — as VP software development, moving on to be CIO and then VP business innovation. He also has served as senior director for computer technology company Oracle.
"Since our founding, 8th Day has built technology designed to help our customers best serve their patients," Loschinskey said. "The same patient-first mentality is woven into Diplomat's culture, making this partnership all the more exciting. I'm proud to join such an innovative company as Diplomat."
FDA approves Novo Nordisk’s Fiasp fast-acting insulin
SILVER SPRING, Md. — The Food and Drug Administration has approved a new fast-acting mealtime insulin from Novo Nordisk. The agency granted approval to Fiasp to treat adults with diabetes.
The drug is a formulation featuring the company’s NovoLog insulin aspart developed with the aim of achieving properties that more closely match the natural physiological insulin mealtime response of someone without diabetes.
“We are very pleased that Fiasp will now also be available to people with diabetes in the United States,” Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. “The fast action profile of Fiasp allows people with diabetes convenient timing in terms of when to take their insulin in connection with meals to achieve the optimal blood sugar control.”
Mylan launches generic Gleevec
HERTFORDSHIRE, England, and PITTSBURGH — Mylan is expanding its offering of oncology generics with its latest introduction. The company has launched its generic of Gleeven (imatinib mesylate) tablets.
The drug is approved to treat multiple indications, including several blood cancers, the company said. The drug had U.S. sales of approximately $1.7 billion for the 12 months ended July 31, according to QunitilesIMS data. The product will be available in 100- and 400-mg dosage strengths.